🟢 BioLineRx is trading 5.37% up in pre-market amid a 2.61% biotech pre-market gain

BioLineRx is trading at $2.55, up 5.37%, with the broader biotech sector’s 2.61% pre-market gain the strongest available explanation for the move.

• No clear company-specific announcement surfaced for September 23, 2026.
• BioLineRx’s annual shareholder meeting is scheduled for September 23.
• GLIX1 data presentations at EANO 2026 begin September 24; both events may support interest but do not directly explain the move.